Experiences with Next-Generation Sequencing in Relapsed Acute Myeloid Leukemia: A Patient Case Series

Keywords: Acute myeloid leukemia (AML); next-generation sequencing (NGS); relapse; evolution; devolution; therapeutic targets.

To the editor.

Next-generation sequencing (NGS) has opened the opportunity for assessing the unique clonal composition of patients with acute myeloid leukemia (AML), not only at the beginning but also within the course of the disease, and particularly at relapse. The molecular genetic characterization of the clonal composition has therapeutic relevance, as a number of molecularly directed treatment options have recently become available. Since relapse of AML remains a major clinical challenge, comprehensive diagnostics during follow-up and at relapse has become an increasingly important pillar of clinical decision making. In the current manuscript, we have applied myeloid NGS panel sequencing to compare the genetic profiles of six illustrative AML patients at initial diagnosis and at relapse. We found that NGS has the potential to identify clonal molecular stability, evolution, and devolution in addition to co-occurring changes on the cytogenetic level, all of which can occur alone or in combination. We discuss these patients in detail, covering clinical, molecular, and cytogenetic, as well as therapeutic aspects.

The increasing use of NGS has been enabled by a number of commercially available panels that cover the most frequently mutated genes. In contrast to traditional diagnostic tools (i.e., cytomorphology, cytogenetics, qPCR) that provide classification and prognostic information only within certain categories, molecular profiling by NGS enables us to depict a unique genetic make-up for each AML patient. Genetic information provides crucial parameters within the current AML classification systems1,2 and has not only an impact on prognosis but also influences treatment options.

However, despite improving remission rates, around 40-60% of AML patients will ultimately relapse3, which remains the major determinant of outcome. At relapse, AML patients can either present with the same genetic mutation pattern as observed at initial diagnosis (clonal stability), or present with higher complexity, e.g., through the acquisition of additional mutations (clonal evolution), or lose some of the initial mutations at relapse (clonal devolution), or, alternatively, show both gains and losses of mutations.4-6

Concerning the pathophysiologic mechanisms involved during clonal evolution at relapse, our current paradigms suggest that pre-existing clones (or subclones) may gain a survival advantage under the selective chemotherapeutic pressure.6 We have recently provided a comprehensive overview of the current knowledge of NGS during relapse of AML.7 Here, we present six illustrative patient studies observed during clinical practice to demonstrate characteristic genetic scenarios accompanying hematologic relapse of AML following intensive chemotherapy. All patients were treated and analyzed by cytogenetics and myeloid NGS panels at diagnosis and at relapse at our department according to the methodology described in Table 1. The sensitivity of NGS analyses was limited to a 5% variant allele frequency (VAF) at diagnosis, and 1% at follow-up as the exact mutation localizations were known.

Patient #1: Molecular and cytogenetic stability at relapse after intensive chemotherapy. A 51-year-old male patient presented with de novo AML, FAB M1, 46, XY, and bone marrow (BM) blasts >90%. Fragment analysis revealed an FLT3-ITD with a mutant/wild-type ratio of >0.5, and PCR detected an NPM1 (type B) mutation. No additional mutations were detected by NGS. Standard induction chemotherapy (cytarabine/idarubicin) followed by cytarabine/daunorubicin) induced complete morphologic remission (CR) with minimal/measurable residual disease (MRD) positivity according to HOVON-132 for the previously known NPM1 mutation. After high-dose chemotherapy (HDCT) with busulfan/cyclophosphamide and...
Table 1: Examples of six AML patients relapsing after intensive chemotherapy; NGS is performed at diagnosis and relapse.

| Patient # | age, sex | AML subtype | Genetic profile at initial AML diagnosis | Genetic profile at relapse |
|-----------|----------|-------------|-----------------------------------------|---------------------------|
| 51; M†    | 51; M†   | de novo, FAB M1 | 46,XY[20]; FLT3-ITD ((ratio (mut/wt) >0.5%)); NPM1 (type B) [c.863_864insCATG, p.Trp288Cysfs*12]. | 46,XY[20]; FLT3-ITD (ratio (mut/wt) <0.5%); NPM1 (type B) [c.863_864insCATG, p.Trp288Cysfs*12]; VAF: 51%. |
| 63; M††   | 63; M††  | sAML (post MDS) | 46,XY[20]; AXXL1 [c.1934dup, p.Gly646Trpfs*12]; VAF 44%]; RUNXI [c.776_780delTTAAC, p.Phe259Serfs*339; VAF 54%]; EHZH [c.1409A>T, p.Gln470Leu; VAF 100%]; SF3B1 [c.2098A>G, p.Lys700Glu; VAF 50%]; NRAS [c.38G>A, p.Gly13Asp; VAF 11%]; TET2 [c.1630C>T, p.Arg544*; VAF 5%]; TN1 [c.6772C>T, p.Arg2258*; VAF 3.1%]. | 46,XY[20]; AXXL1 [c.1934dup, p.Gly646Trpfs*12]; VAF 38%]; RUNXI [c.776_780delTTAAC, p.Phe259Serfs*339; VAF 40%]; EHZH [c.1409A>T, p.Gln470Leu; VAF 100%]; SF3B1 [c.2098A>G, p.Lys700Glu; VAF 34%]; NRAS [c.38G>A, p.Gly13Asp; VAF 13%]; TET2 [c.1630C>T, p.Arg544*; VAF 43%]; TN1 [c.6772C>T, p.Arg2258*; VAF 18%]. |
| 72; F††   | 72; F††  | de novo, FAB M2 | 45, X, -X, der(1)(t(1;13)(q41;q12),del(5)(q1-14q32),del(8)(q13q22),add(3)(p24)-7,8,add(11)(p?)(24),16,-17,18,+mar[11]/46,XX[1]; TP53 [c.613T>G, p.(Tyr205Asp); VAF 43%]; c.841G>C, p.Asp281His; VAF 43%]. | 46,XX[20]; TP53 [c.613T>G, p.(Tyr205Asp); VAF 43%]; c.841G>C, p.Asp281His; VAF 43%]. |
| 41; M†    | 41; M†   | sAML (post MDS) | 46,XY[20]; KRAS [c.437C>T, p.Ala146Val; VAF 9%]; | 46,XY[20]; KRAS negative; WT1 [c.1105_1106insATCCTGC, p.Arg369Hisfs*18; VAF 14%]; & [c.1340G>T, p.Arg162Lys; VAF 12%]; FLT3-ITD (ratio=0.202). |
| 65; F†    | 65; F†   | de novo, FAB M1 | 46,XX,del(9)(q12q32)[15]; NPM1 (type D) [c.863_864insCATG, p.W828S*12]; DNMT3A [c.2644C>T, p.Arg882Cys; VAF 43%]; | 46,XX[20]; NPM1 (type A) [c.860_863dup, p.Trp288Cysfs*12]; DNMT3A [c.2644C>T, p.Arg882Cys; VAF 43%]; TET2 [c.3302_3303delCT, p.Leu101Glnfs*2; VAF 34%]. |
| 62; F††   | 62; F††  | de novo, FAB M1 | 46,XX[20]; RUNXI [c.845G>A, p.Asp162Lys; VAF 31%]; | 47,XY,+,21[13];46,XX[7]; RUNXI [c.485G>A, p.Arg162Lys; VAF 32%]; & [c.780_781insAA, p.Pro261Asnfs*5; VAF 8%]; *occurring 5 months after start of relapse therapy. |

A. acutemajdulmyeloid leukemia; F., female; FAB, French-American-British classification of AML; M., male; MDS, myelodysplastic syndrome; mut/wt., mutated/wild-type; sAML, secondary AML; VAF, variant allele frequency. † NGS with Ampiseq EA myeloid panel (Thermo Fisher Scientific, Reinach, Switzerland; 30 genes/hotspots) at diagnosis and relapse. †† NGS with Ampiseq EA myeloid panel at diagnosis and Oncomine myeloid panel (Thermo Fisher Scientific, Reinach, Switzerland; 40 genes/hotspots) at relapse.

Autologous stem cell transplantation (ASCT), the patient achieved molecular MRD-negative CR1 as assessed by PCR/fragment analysis. 4.5 months after ASCT, both the NPM1 and FLT3-ITD mutations re-emerged, followed by an overt hematologic relapse one month later. NGS and cytogenetics revealed no additional changes. Salvage therapy (cladribine, cytarabine, and idarubicin; CLA-Ida) plus sorafenib resulted in morphologic CR2, albeit with the persistence of the NPM1 and FLT3-ITD mutations. Matched-related myeloablative allogeneic HSCT (11/2017) was performed, but molecular MRD persisted at 3 months.
post-transplant, and sorafenib was once more initiated and combined with azacitidine (AZA). At the time of this report, the patient remained in molecular CR2, meanwhile under continued sorafenib monotherapy.

**Patient #2: Molecular and cytogenetic stability at relapse after allogeneic transplant.** A 63 years old male patient developed s-AML following 4 years of MDS with a “wait and watch” approach. At the time of s-AML, the karyotype was normal, and NGS revealed nine mutations in ASXL1, RUNX1, EZH2, CEBPA, DNMT3A, SF3B1, NRAS, TET2, and NF1. The patient underwent cytarabine/idarubicin induction followed by myeloablative allogeneic HSCT in CR1 with the molecular persistence of all mutations. Subsequently, the patient developed hematologic relapse (d+78 after HSCT), demonstrating a normal karyotype and the identical mutations seen before. The patient was resistant to AZA, donor lymphocyte infusion, and gemtuzumab ozogamicin and died 4 months after HSCT due to progressive disease.

**Patient #3: Molecular stability with cytogenetic clonal devolution at relapse.** A 72 years old female patient was diagnosed with high-risk de novo AML M2 with a complex multi-clonal karyotype. NGS revealed two different mutations in TP53. The patient was refractory to standard induction chemotherapy, but second-line decitabine (10 cycles) resulted in CR1, and NGS documented clearance of the TP53 mutations. Due to poor veins, decitabine therapy was switched to AZA. Relapse occurred 11.5 months after the achievement of CR1; the karyotype was normal, whereas both TP53 mutations remained detectable. Decitabine treatment combined with sorafenib failed to induce any response. The patient died one month after relapse detection due to progressive disease.

**Patient #4: Simultaneous clonal evolution and devolution at relapse.** Forty-one years old male patient presented with de novo AML, FAB M1, with a 9q deletion. PCR revealed NPM1 mutation type D. The patient received induction consisting of cytarabine/idarubicin/laromustin followed by busulfan/cyclophosphamide HDCT/ASCT. Following a period of long-lasting remission with MRD negativity for the NPM1 type D mutation over 8 years, the patient showed a 4-log increase of the NPM1 mutation load detected by qPCR. Still being at hematologic CR1, NPM1 re-appearance was detected by qPCR as well as NGS but surprisingly identified type A instead of type D. Yet, the latter was also confirmed retrospectively by NGS at initial diagnosis. In addition, a DNMT3A mutation was discovered in the relapse sample. Subsequent qPCR assay with a primer designed for type A revealed a ratio of 6.285. Six weeks later, BM cytomorphology and immunophenotyping revealed up to 35% myeloid blasts corresponding to overt AML M2. Cytogenetics revealed a normal karyotype, with a lack of the 9q deletion documented at first diagnosis. We have previously described this switch of NPM1 types (from type D to type A). The DNMT3A mutation identified at relapse was retrospectively detected in stored material from initial diagnosis. The patient underwent salvage chemotherapy, followed by busulfan/melphalan HDCT/ASCT. Subsequently, maintenance therapy with AZA was started resulting in NPM1 MRD-negative CR2 ongoing 22 months after diagnosis of relapse. Finally, a TET2 mutation was also found retrospectively with a variant allele frequency (VAF) of 43% in addition to DNMT3A (47% VAF) in the autologous stem cell harvest preceding the 2nd ASCT. TET2 and DNMT3A mutations persisted at last follow-up (34%/43% VAF) despite NPM1 type A mutation clearance suggesting an interpretation of clonal hematopoiesis of indeterminate potential (CHIP).

**Patient #5: Both clonal evolution and devolution at relapse.** A 65 years old female patient presented with de novo AML, FAB M1, with a 9q deletion. PCR revealed NPM1 mutation type D. The patient received induction consisting of cytarabine/idarubicin/laromustin followed by busulfan/cyclophosphamide HDCT/ASCT. Following a period of long-lasting remission with MRD negativity for the NPM1 type D mutation over 8 years, the patient showed a 4-log increase of the NPM1 mutation load detected by qPCR. Still being at hematologic CR1, NPM1 re-appearance was detected by qPCR as well as NGS but surprisingly identified type A instead of type D. Yet, the latter was also confirmed retrospectively by NGS at initial diagnosis. In addition, a DNMT3A mutation was discovered in the relapse sample. Subsequent qPCR assay with a primer designed for type A revealed a ratio of 6.285. Six weeks later, BM cytomorphology and immunophenotyping revealed up to 35% myeloid blasts corresponding to overt AML M2. Cytogenetics revealed a normal karyotype, with a lack of the 9q deletion documented at first diagnosis. We have previously described this switch of NPM1 types (from type D to type A). The DNMT3A mutation identified at relapse was retrospectively detected in stored material from initial diagnosis. The patient underwent salvage chemotherapy, followed by busulfan/melphalan HDCT/ASCT. Subsequently, maintenance therapy with AZA was started resulting in NPM1 MRD-negative CR2 ongoing 22 months after diagnosis of relapse. Finally, a TET2 mutation was also found retrospectively with a variant allele frequency (VAF) of 43% in addition to DNMT3A (47% VAF) in the autologous stem cell harvest preceding the 2nd ASCT. TET2 and DNMT3A mutations persisted at last follow-up (34%/43% VAF) despite NPM1 type A mutation clearance suggesting an interpretation of clonal hematopoiesis of indeterminate potential (CHIP).
accompanied by an additional, i.e., second, RUNX1 mutation suggesting further molecular clonal evolution. Palliative therapy was administered by decitabine (9 cycles), then with low-dose cytarabine with glasdegib (hedgehog pathway inhibitor), and finally, sorafenib. The patient succumbed to refractory disease one month after the sorafenib start and 15 months after the first relapse.

**Conclusions.** As demonstrated by our case series, each patient may present with an individual genetic composition at relapse of AML. Compared to the initial diagnosis, this may comprise clonal stability, evolution, or devolution alone or in combination both at the molecular and/or cytogenetic level. Consequently, the genetic characterization during relapse may identify novel lesions treatable by targeted therapies or may open new pathways for bridging strategies towards allogeneic HSCT. This can be illustrated, for example, by FLT3 mutations, which are emerging in around 10% of AML patients at relapse, and may provide an option for specific FLT3 inhibitor treatment, such as midostaurin, gilteritinib or others. Similarly, both IDH1 (ivosidenib) and IDH2 (enasidenib) inhibitors were recently approved in AML with the respective mutations. Knowledge of relapse genetics may imply consequences also for prognosis. Adverse prognostic markers, such as TP53 mutations emerging at relapse, may allow timely initiation of donor search for subsequent allogeneic HSCT. Accordingly, the development of distinct diagnostics and therapeutic algorithms for clonal stability, evolution, and devolution, as well as defining of “founder” mutations in relapsed AML settings may further ease the management of such patients. Anticipating anti-relapse treatment with targeted agents, the determination of mutant allele frequencies is of high importance as these provide a sensitive diagnostic tool to assess response on the molecular level and predict progression over time. In conclusion, NGS may be discussed for all patients at AML relapse. Due to recent improvements in treatment options and an increasing understanding of the molecular drivers of AML, therapy in the relapse situation becomes more and more individualized, and, consequently, NGS will gain increasing importance in this scenario.

Johanna Flach1*, Evgenii Shumilov2*, Naomi Porret3,4, Inna Shakhanova1, Myriam Legros4, Marie-Noëlle Kronig6, Raphael Joncourt3,4, Ulrike Bacher3,4**, and Thomas Pabst6**.

1. Department of Hematology and Oncology, Medical Faculty Mannheim of the Heidelberg University, Mannheim, Germany.
2. Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), Göttingen, Germany.
3. University Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland.
4. Center of Laboratory Medicine (ZLM)/University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, Bern, Switzerland.
5. Department of Nephrology and Rheumatology, University Medicine Göttingen (UMG), Göttingen, Germany.
6. Department of Medical Oncology, Inselspital, Bern University Hospital, Bern, Switzerland.

*JF and ES contributed equally and should be considered first authors; ** UB and TP contributed equally and should be considered last authors.

**Competing interests:** The authors declare no conflict of Interest.

Correspondence to: Ulrike Bacher, MD. Department of Hematology and Center of Laboratory Medicine (ZLM); Inselspital, Bern University Hospital, University of Bern; Bern, Switzerland; Tel.: +41-31-632-1390; Fax. +41-31-632-3406. E-mail: veraulrike.bacher@insel.ch

Thomas Pabst, MD. Department of Medical Oncology; Inselspital, Bern University Hospital, University of Bern; Bern, Switzerland; Tel.: +41-31-632 8430; Fax: +41-31-632-3410. E-mail: thomas.pabst@insel.ch

**References:**

1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391-2405. [https://doi.org/10.1182/blood-2016-03-643544](https://doi.org/10.1182/blood-2016-03-643544)

2. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129:424-447. [https://doi.org/10.1182/blood-2016-08-733196](https://doi.org/10.1182/blood-2016-08-733196)

3. Burnett AK, Goldstone A, Hills RK, et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol 2013;31:1293-1301. [https://doi.org/10.1200/JCO.2011.40.5977](https://doi.org/10.1200/JCO.2011.40.5977)

4. Greif PA, Hartmann L, Vosberg S, et al. Evolution of Cyto genetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients. Clin Cancer Res 2018;24:1716-1726. [https://doi.org/10.1158/1078-0432.CCR-17-2344](https://doi.org/10.1158/1078-0432.CCR-17-2344)

5. Quek L, Ferguson P, Metzner M, et al. Mutational analysis of disease
relapse in patients allografted for acute myeloid leukemia. Blood Adv 2016;1:193-204.  
https://doi.org/10.1182/bloodadvances.2016000760  
PMid:29296935 PMCID:PMC5737177

6. Wong TN, Ramsingh G, Young AL, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 2015;518:552-555.  
https://doi.org/10.1038/nature13968  
PMid:25487151 PMCID:PMC4403236

7. Flach J, Shamilov E., Wiedemann, G., et al. Clinical potential of introducing next-generation sequencing in patients at relapse of acute myeloid leukaemia. Hematol Oncol 2020;1-7.  
https://doi.org/10.1002/hon.2739  
PMid:32306411

8. Shamilov E, Flach J, Joncourt R, et al. Clinical value of molecular MRD monitoring by next-generation sequencing in patients with IDH2 mutated AML. Leuk Lymphoma 2019;60:2588-2590.  
https://doi.org/10.1080/10428194.2019.1585838  
PMid:30998101

9. Bacher U, Porret N, Joncourt R, et al. Pitfalls in the molecular follow up of NPM1 mutant acute myeloid leukemia. Haematologica 2018;103:e486-e488.  
https://doi.org/10.3324/haematol.2018.192104  
PMid:29903758 PMCID:PMC6165800

10. McCormick SR, McCormick MJ, Grutkoski PS, et al. FLT3 mutations at diagnosis and relapse in acute myeloid leukemia: cytogenetic and pathologic correlations, including cuplike blast morphology. Arch Pathol Lab Med 2010;134:1143-1151.  
11. Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med 2019;381:1728-1740.  
https://doi.org/10.1056/NEJMoa1902688  
PMid:31665578

12. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med 2017;377:454-464.  
https://doi.org/10.1056/NEJMoa1614359  
PMid:28644114 PMCID:PMC5754190

13. Norsworthy KJ, Luo L, Hsu V, et al. FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation. Clin Cancer Res 2019;25:3205-3209.  
https://doi.org/10.1158/1078-0432.CCR-18-3749  
PMid:30692099

14. Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 2017;130:722-731.  
https://doi.org/10.1182/blood-2017-04-779405  
PMid:28588020 PMCID:PMC5572791